Expanded geographical rights to brodalumab for LEO Pharma

14 August 2019

Danish dermatology specialist LEO Pharma says it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum in the European Union and Siliq in other regions) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licensing agreement with Bausch Health (TXS: BHC).

The new agreement includes countries with significantly high unmet need, such as Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia.

This complements the ongoing licensing agreement between LEO Pharma and the drug’s developer, Anglo-Swedish pharma major AstraZeneca (LSE: AZN), to develop and market brodalumab for the treatment of moderate-to-severe psoriasis in Europe. Bausch continues to hold the rights for the US and Canada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK